PE20221515A1 - Oxinitruro de piridina, metodo para su preparacion y uso de este - Google Patents
Oxinitruro de piridina, metodo para su preparacion y uso de esteInfo
- Publication number
- PE20221515A1 PE20221515A1 PE2022000407A PE2022000407A PE20221515A1 PE 20221515 A1 PE20221515 A1 PE 20221515A1 PE 2022000407 A PE2022000407 A PE 2022000407A PE 2022000407 A PE2022000407 A PE 2022000407A PE 20221515 A1 PE20221515 A1 PE 20221515A1
- Authority
- PE
- Peru
- Prior art keywords
- oxinitride
- pyridine
- preparation
- refers
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910863718 | 2019-09-12 | ||
| CN201911094782 | 2019-11-11 | ||
| CN202010531381 | 2020-06-11 | ||
| CN202010923311 | 2020-09-04 | ||
| PCT/CN2020/114700 WO2021047622A1 (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221515A1 true PE20221515A1 (es) | 2022-10-04 |
Family
ID=74866555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000407A PE20221515A1 (es) | 2019-09-12 | 2020-09-11 | Oxinitruro de piridina, metodo para su preparacion y uso de este |
Country Status (17)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024509939A (ja) * | 2021-03-11 | 2024-03-05 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | ピリジン窒素酸化物の結晶形態およびその使用 |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| SMT202600064T1 (it) | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| EP4534529A4 (en) * | 2022-06-02 | 2026-06-03 | Shanghai Jemincare Pharmaceuticals Co Ltd | PROCESS FOR PREPARING A PYRIDINE OXYNITRIDIDE COMPOUND |
| TW202413335A (zh) * | 2022-06-22 | 2024-04-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Ｎａｖ１．８抑制劑 |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| TW202434235A (zh) * | 2023-01-18 | 2024-09-01 | 芬蘭商奧利安公司 | ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法 |
| CN121419965A (zh) * | 2023-06-14 | 2026-01-27 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物的盐型、共晶及其制备方法和应用 |
| WO2024255833A1 (zh) * | 2023-06-14 | 2024-12-19 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物与富马酸的共晶体及其组合物、用途和制备方法 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| WO2025124502A1 (zh) * | 2023-12-13 | 2025-06-19 | 武汉人福创新药物研发中心有限公司 | 一种Nav1.8抑制剂化合物及其盐、多晶型和用途 |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| BRPI0611596A2 (pt) * | 2005-06-21 | 2010-09-21 | Mitsui Chemicals Inc | derivado de amina e inseticida contendo o mesmo |
| MX2008013194A (es) * | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| JP2010047480A (ja) * | 2006-12-19 | 2010-03-04 | Mitsui Chemicals Inc | 虫害の予防方法 |
| EP2212290B1 (en) * | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| MX2010003864A (es) * | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| US9656959B2 (en) * | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| KR102226587B1 (ko) * | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| CN105026373B (zh) * | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| BR112015018284B1 (pt) * | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| SG11202100130QA (en) * | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
-
2020
- 2020-09-11 KR KR1020227012157A patent/KR20220101606A/ko not_active Ceased
- 2020-09-11 EP EP20863934.4A patent/EP4043437A4/en active Pending
- 2020-09-11 JP JP2022516434A patent/JP2022548104A/ja active Pending
- 2020-09-11 CN CN202080037787.2A patent/CN113906013B/zh active Active
- 2020-09-11 CN CN202010957957.0A patent/CN112479996B/zh active Active
- 2020-09-11 PH PH1/2022/550584A patent/PH12022550584A1/en unknown
- 2020-09-11 GE GEAP202015928A patent/GEP20247688B/en unknown
- 2020-09-11 AU AU2020346951A patent/AU2020346951A1/en not_active Abandoned
- 2020-09-11 CN CN202410255352.5A patent/CN118146148A/zh active Pending
- 2020-09-11 TW TW109131318A patent/TWI770607B/zh active
- 2020-09-11 BR BR112022004495A patent/BR112022004495A8/pt unknown
- 2020-09-11 WO PCT/CN2020/114700 patent/WO2021047622A1/zh not_active Ceased
- 2020-09-11 CA CA3150400A patent/CA3150400A1/en active Pending
- 2020-09-11 MX MX2022003032A patent/MX2022003032A/es unknown
- 2020-09-11 US US17/642,020 patent/US20230303495A9/en not_active Abandoned
- 2020-09-11 GE GEAP202415928A patent/GEAP202415928A/en unknown
- 2020-09-11 PE PE2022000407A patent/PE20221515A1/es unknown
-
2022
- 2022-03-11 CL CL2022000619A patent/CL2022000619A1/es unknown
- 2022-04-11 CO CONC2022/0004594A patent/CO2022004594A2/es unknown
- 2022-04-11 ZA ZA2022/04100A patent/ZA202204100B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004495A2 (pt) | 2022-05-31 |
| EP4043437A4 (en) | 2023-10-04 |
| CN112479996A (zh) | 2021-03-12 |
| US20230303495A9 (en) | 2023-09-28 |
| CN118146148A (zh) | 2024-06-07 |
| GEP20247688B (en) | 2024-11-11 |
| CN113906013B (zh) | 2024-03-12 |
| CN113906013A (zh) | 2022-01-07 |
| US20230026907A1 (en) | 2023-01-26 |
| TW202114990A (zh) | 2021-04-16 |
| CA3150400A1 (en) | 2021-03-18 |
| CL2022000619A1 (es) | 2022-10-28 |
| EP4043437A1 (en) | 2022-08-17 |
| CO2022004594A2 (es) | 2022-07-08 |
| GEAP202415928A (en) | 2024-07-10 |
| ZA202204100B (en) | 2024-04-24 |
| CN112479996B (zh) | 2023-05-26 |
| JP2022548104A (ja) | 2022-11-16 |
| MX2022003032A (es) | 2022-07-12 |
| PH12022550584A1 (en) | 2024-03-04 |
| WO2021047622A1 (zh) | 2021-03-18 |
| BR112022004495A8 (pt) | 2023-04-18 |
| AU2020346951A1 (en) | 2022-04-28 |
| KR20220101606A (ko) | 2022-07-19 |
| TWI770607B (zh) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000115A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| ECSP23095485A (es) | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio | |
| MX2024015459A (es) | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico | |
| PE20191552A1 (es) | Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3) | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| MD3405471T2 (ro) | Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| MX2015009602A (es) | Piridona amidas como moduladores de canales de sodio. | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| CO2023000056A2 (es) | Derivados de amidopirimidona | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| PY2039849A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| ECSP045420A (es) | Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos | |
| UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| CL2020000553A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. | |
| MX2022000598A (es) | Preparacion de compuestos antibacterianos. | |
| CU20200100A7 (es) | Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen | |
| BR112017021083A2 (pt) | piridopirimidinonas e seu uso como moduladores do receptor de nmda | |
| UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos | |
| AR040456A1 (es) | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana | |
| EA202092955A1 (ru) | Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |